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Introduction: The immature platelet and immature reticulocyte fractions represent the ratios
of  platelets and reticulocytes recently released into the circulation and thus with higher RNA
content. They are considered early indicators of bone marrow recovery.
Objective: The aim of this study was to determine the reference ranges for the immature
platelet and reticulocyte fractions of hematologically normal individuals in a university
hospital.
Methods: Venous blood samples collected in ethylenediaminetetraacetic acid K3 were ana-
lyzed  using a Sysmex XE-5000TM analyzer. Individuals with platelet and reticulocyte counts
within the reference ranges, and a blood count within the laboratory’s screening criteria
were included. Individuals with clinical conditions that could affect hematological results
were excluded. The immature platelet fraction, high, medium and low ﬂuorescence retic-
ulocyte fractions and reticulocyte hemoglobin equivalent were evaluated. The reference
ranges were determined according to the recommendations of the International Federation
of  Clinical Chemistry.
Results: One hundred and thirty-two outpatients were evaluated. The mean age was 44
years (range: 13–80 years), 72 (54.5%) were women treated in a university hospital. The
mean platelet count was 250.8 × 109/L and the mean reticulocyte count was 0.052 × 109/L.
The  following reference ranges were obtained: immature reticulocyte fraction 1.6–12.1%,
the  high, medium and low ﬂuorescence reticulocyte fractions were 0.0–1.7%, 1.6–11.0%
and  87.9–98.4%, respectively, the reticulocyte hemoglobin equivalent was 30.0–37.6% andimmature platelet fraction was 0.8–5.6%. There was a statistically signiﬁcant difference (p-
n genders in respect to the immature platelet fraction with 0.8–4.7% forvalue = 0.006) betweefemales and 0.7–6.1% for males. The immature reticulocyte fraction was directly correlated
with  the reticulocyte count.
∗ Corresponding author at: Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, 2350, 90035-903 Porto Alegre, RS, Brazil.
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Conclusion: Determining the reference range is critical to the introduction of a new
parameter. The reference ranges obtained herein corroborate those reported in previ-
ous  publications and will contribute to the clinical and laboratory application of the
indices.
©  2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
I
R
i
h
d
t
r
u
r
o
o
b
h
a
I
p
t
c
g
s
l
i
l
l
c
(
t
p
c
e
o
e
u
u
i
e
a
b
t
f
I
p
rntroduction
ecent advances in the ﬁeld of hematology analyzers used
n clinical laboratories allow the determination of additional
ematologic parameters, providing useful information for the
iagnosis and/or treatment of various pathologies.1 Among
hese parameters are the immature fractions of platelets and
eticulocytes.1–3
The immature platelet fraction (IPF) and immature retic-
locyte fraction (IRF) are young cells that have recently been
eleased into the circulation, and are considered indicators
f bone marrow recovery.1–3 They are important in vari-
us clinical situations, such as thrombocytopenia, anemia,
one marrow regeneration following the transplantation of
ematopoietic stem cells and after chemotherapy.2,4–13
The IPF and IRF are determined using hematology
nalyzers with ﬂuorescence and light scatter technology.
mmature fractions have larger amounts of RNA than mature
latelets and reticulocytes. Thus, the use of ﬂuorescent probes
hat label the RNA permit the differentiation and quantiﬁ-
ation of the IRF and IPF.1–3,6 Automated systems provide a
raphic display of the different populations according to the
ize and amount of RNA. Based on this, the indices are calcu-
ated as a percentage of total reticulocytes and platelets.1–3,6
Different populations of reticulocytes are separated accord-
ng to the size and the amount of RNA and classiﬁed as being
ow (LFR), medium (MFR) or high (HFR) ﬂuorescence reticu-
ocyte fractions. The combined counts of the HFR and MFR
orrespond to IRF. The reticulocyte hemoglobin equivalent
Ret-He) parameter corresponds to the hemoglobin content of
he reticulocytes, and is studied as an indicator of the incor-
oration of iron in reticulocytes.15–18
Advances in automation have provided additional blood
ount parameters that enable new interpretations of the
xamination. However, clinical application can only occur
nce the reference ranges have been determined with knowl-
dge of pre-analytical variables (time, temperature, anticoag-
lants) and standardization of the methodology.1,2,16,17,19–21
Some reference ranges have been calculated by the man-
facturer, while others have not yet been determined. Thus,
t is recommended that each laboratory calculates the refer-
nce range for its population, taking into account the routine
nd the methodology used.22–24 Subjects should be stratiﬁed
y age and gender and meet strict criteria in the selection of
he individuals in the pre-analytical and analytical phases and
or statistical analysis.22–24This study aims to determine the reference ranges for the
PF, IRF, LFR, MFR, HFR and Ret-HE in hematologically normal
atients treated at a university hospital, in order to study the
oles of the parameters as predictors of engraftment in bone(http://creativecommons.org/licenses/by-nc-nd/4.0/).
marrow transplantation, one of their main clinical applica-
tions.
Methods
Venous blood samples collected in ethylenediaminetetraace-
tic acid K3 (EDTA-K3) were analyzed in a Sysmex XE-5000TM
analyzer (Sysmex Corporation, Japan). To minimize variations
due to sample age, all assays were performed within four
hours of collection; the samples were kept at room temper-
ature until the time of analysis. The analyzer uses the same
reagent to measure the IPF and IRF in the reticulocyte channel.
The platelet detection method employs hydrodynamic
focus and direct current technology. The IPF and IRF are deter-
mined by ﬂuorescence and light scatter using ﬂuorescent
RNA markers.1–3 The Ret-He is obtained by ﬂow cytometry
technology using a polymethine dye, speciﬁc for RNA/DNA.
The forward light scatter intensity correlates to the cellular
hemoglobin content.
Patients with normal blood counts within the screening
criteria established by the laboratory such as hemoglobin
greater than 12.0 g/dL and platelet and reticulocyte count val-
ues within the normal ranges (platelet count greater than
150.0 × 109/L and reticulocytes 25–80 × 109/L) were included.
Patients with diabetes, human immunodeﬁciency virus (HIV),
cardiovascular diseases, pregnant women, hematologic dis-
eases, cancer, and thyroid disease were excluded, as these
conditions may affect the hematological results.19–21
The IPF, IRF, the reticulocyte ratios (HFR, MFR and LFR) and
Ret-He were evaluated. Assays were routinely submitted to
internal and external quality controls.
Statistical  analysis
The reference ranges were determined using of the Statistical
Package for Social Sciences version 18.0 (SPSS Inc., Chicago,
IL, USA). Symmetric variables are expressed as the mean and
standard deviation, while asymmetric variables are expressed
as the median, 2.5–97.5 percentiles within a 95% conﬁdence
interval, as recommended by the International Federation of
Clinical Chemistry (IFCC).22–24 Spearman’s and Pearson’s cor-
relation tests were also used.
ResultsOne hundred and thirty-two outpatients were evaluated.
The mean age was 44 years (range: 13–80) and 72 (54.5%)
were women treated at a university hospital. The mean
platelet count was 250.8 × 109/L and the mean reticulocyte
312  rev bras hematol hemoter.
Table 1 – Reference interval and median for reticulocyte
index.
Reference range Median
LFR (%) 87.89–98.37 94.65
MFR (%) 1.6–11.04 4.9
HFR (%) 0–1.7 0.3
IRF (%) 1.6–12.1 5.35
Ret-He (%) 30.0–37.6 33.8
LFR: low ﬂuorescence ratio; MFR: medium ﬂuorescence ratio; HFR:
high ﬂuorescence ratio; IRF: immature reticulocyte fraction; Ret-He:
reticulocyte hemoglobin equivalent.
Table 2 – Reference range and median for immature
platelet fraction.
Reference range Median
Women (%) 0.7–4.7 2.0
Men (%) 0.6–6.1 2.6
r
cancer after chemotherapy and hematopoietic stem cellTotal (%) 0.8–5.5 2.2
concentration was 1.1% (range: 0.6–1.7%) with a count of
52 × 109/L (range: 49–54 × 109/L).
The median value of the IRF was 5.3% with a range of
1.6–12.1%. The reference ranges of the HFR, MFR and LFR were
0.0–1.7%, 1.6–11.0% and 87.9–98.4%, respectively. The mean
Ret-He was 33.8% with a range of 30.0–37.6% (Table 1).
The median IPF was 2.2% with a range of 0.8–5.6%. A
statistically signiﬁcant difference (p-value = 0.006) between
genders was only found for the IPF, with 2.0% for females
(range: 0.8–4.7%) and 2.6% for males (range: 0.7–6.1%). The IRF
presented a direct correlation (Spearman Rank-order Coefﬁ-
cient = 0.40) with the reticulocyte count (Table 2).
Discussion
Although not directly used in clinical decision making, the ref-
erence range is critical to the introduction of new parameters
and the interpretation of laboratory results.22–24 The reference
range shows the variation of likely values in ‘healthy’ individ-
uals who  do not present clinical conditions that can affect the
studied variables.22–24
Immature platelets and immature reticulocytes are pre-
cursor cells recently released into the blood stream that
contain larger amounts of RNA. Thus, they can be distin-
guished from the mature platelets and reticulocytes and
quantiﬁed using RNA ﬂuorescent labeling.1–3 Several studies
have demonstrated the value of these indices in the context
of hematopoietic stem cell transplantation as indicators of
hematopoiesis, in transfusion assessment and the anticipa-
tion of successful engraftment.1–8 The Ret-He is useful in the
evaluation of hematopoiesis, with respect to the incorporation
of iron.14–17
The reference range obtained for the IPF was in accordance
with the studies by Takami et al. (mean 2.0%; range: 0.5–5.7%),9
Gonzalo et al. (median: 2.3%; range: 0.6–7.2%),4 Yamaoka et al.
(mean of 3.0 ± 1%),8 and Briggs et al. (range: 1.1–6.1%).2 The
study by Ko et al. found lower IPF values (range: 0.5–3.3%).18 2 0 1 6;3  8(4):310–313
The reference range for the IRF was similar to that of Gon-
zalo et al. who obtained a median of 4.7% (range: 1.1–11.4%).4
Although they used the same methodology, these studies were
conducted with the use of a Sysmex XE-2100TM analyzer.
Other authors employed other methodologies to determine
the reference ranges for the IPF and IRF and so they were not
compared with the results of the current study.
Determining the reference range involves several steps,
including selection of subjects, methodology and statistical
analysis.22–24 It is essential that it is carried out for new param-
eters that are not widely used by laboratories and clinics. The
reference ranges for the IRF and IPF reported in this study are
consistent with the literature and will contribute to the clinical
application of these indices.
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